{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:10:36Z","timestamp":1761513036205,"version":"3.38.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T00:00:00Z","timestamp":1317772800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s00277-011-1349-2","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T14:32:06Z","timestamp":1317738726000},"page":"577-586","source":"Crossref","is-referenced-by-count":14,"title":["Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients"],"prefix":"10.1007","volume":"91","author":[{"given":"Pervin","family":"Topcuoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutlu","family":"Arat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhit","family":"Ozcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onder","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Ilhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunhan","family":"Gurman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,5]]},"reference":[{"key":"1349_CR1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, M\u00fcller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA, IRIS Investigators (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061. doi: 10.1038\/leu.2009.38","journal-title":"Leukemia"},{"key":"1349_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","volume":"47","author":"J Goldman","year":"2006","unstructured":"Goldman J, Gordon M (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 47:1\u20137. doi: 10.1080\/10428190500407996","journal-title":"Leuk Lymphoma"},{"key":"1349_CR3","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","volume":"6","author":"SI Bearman","year":"1988","unstructured":"Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562\u20131568","journal-title":"J Clin Oncol"},{"key":"1349_CR4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","volume":"91","author":"S Slavin","year":"1998","unstructured":"Slavin S, Nagler A, Naparstek E, Naparstek E, Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756\u2013763","journal-title":"Blood"},{"key":"1349_CR5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.bmt.1704107","volume":"32","author":"M Das","year":"2003","unstructured":"Das M, Saikia TK, Advani SH, Parikh PM, Tawde S (2003) Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 32:125\u2013129. doi: 10.1038\/sj.bmt.1704107","journal-title":"Bone Marrow Transplant"},{"key":"1349_CR6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2006.03.012","volume":"12","author":"A Grig","year":"2006","unstructured":"Grig A, Hughes T (2006) Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Bone Marrow Transplant 12:795\u2013807. doi: 10.1016\/j.bbmt.2006.03.012","journal-title":"Biol Bone Marrow Transplant"},{"key":"1349_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1703323","volume":"29","author":"D Gaziev","year":"2002","unstructured":"Gaziev D, Galimberti M, Polchi P, Angelucci E, Giardini C, Baronciani D, Andreani M, Persini B, Erer B, Sodani P, Manna M, Nicolini G, Visani G, Lucarelli G, AIEOP (2002) Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and\/or interferon at a single center: long-term results. Bone Marrow Transplant 29:1\u20138. doi: 10.1038\/sj\/bmt\/1703323","journal-title":"Bone Marrow Transplant"},{"key":"1349_CR8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1705478","volume":"38","author":"M Krejci","year":"2006","unstructured":"Krejci M, Mayer J, Doubek M, Brychtova Y, Pospisil Z, Racil Z, Dvorakova D, Lengerova M, Horky O, Koristek Z, Dolezal T, Vorlicek J (2006) Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant 38:483\u2013491. doi: 10.1038\/sj.bmt.1705478","journal-title":"Bone Marrow Transplant"},{"key":"1349_CR9","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.bmt.1705190","volume":"36","author":"GJ Ruiz-Arg\u00fcelles","year":"2005","unstructured":"Ruiz-Arg\u00fcelles GJ, G\u00f3mez-Almaguer D, Morales-Toquero A, Guti\u00e9rrez-Aguirre CH, Vela-Ojeda J, Garc\u00eda-Ruiz-Esparza MA, Manzano C, Karduss A, Sumoza A, de-Souza C, Miranda E, Giralt S, Latin American Cooperative Oncohematology Group (2005) The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 36:1043\u20131047. doi: 10.1038\/sj.bmt.1705190","journal-title":"Bone Marrow Transplant"},{"key":"1349_CR10","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","volume":"106","author":"C Crawley","year":"2005","unstructured":"Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M, Vitek A, Mayer J, Zander A, Sierra J, Rambaldi A, Ringden O, Niederwieser D, Apperley JF, Chronic Leukemia Working Party of the EBMT (2005) Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106:2969\u20132976. doi: 10.1182\/blood-2004-09-3544","journal-title":"Blood"},{"key":"1349_CR11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/146532401317070880","volume":"3","author":"G G\u00fcrman","year":"2001","unstructured":"G\u00fcrman G, Arat M, Ilhan O, Konuk N, Beksa\u00e7 M, Celebi H, Ozcan M, Arslan O, Ust\u00fcn C, Akan H, Uysal A, Ko\u00e7 H (2001) Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Cytotherapy 3:253\u2013260. doi: 10.1080\/146532401317070880","journal-title":"Cytotherapy"},{"key":"1349_CR12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"A Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J, Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 352:1087\u20131092. doi: 10.1016\/S0140-6736(98)03030-X","journal-title":"Lancet"},{"key":"1349_CR13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/bbmt.1999.v5.pm10232738","volume":"5","author":"C Ust\u00fcn","year":"1999","unstructured":"Ust\u00fcn C, Arslan O, Beksa\u00e7 M, Ko\u00e7 H, G\u00fcrman G, Oz\u00e7elik T, Yilmaz B, Ilhan O, Akan H, Ozcan M, Demirer T, Uysal A, Konuk N, Arat M, Dilek I, Celebi H, Coskun HS (1999) A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Biol Blood Marrow Transplant 5:28\u201335, S1083-8791(99)50027-X","journal-title":"Biol Blood Marrow Transplant"},{"key":"1349_CR14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0955-3886(00)00123-5","volume":"24","author":"G G\u00fcrman","year":"2001","unstructured":"G\u00fcrman G, Dilek I, Arslan O, Arat M, Beksa\u00e7 M, Ilhan O, Ozcan M, Akan H, Dalva K, Konuk N, Uysal A, Ko\u00e7 H (2001) The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation. Transfus Apher Sci 24:23\u201328, S0955-3886(00)00123-5","journal-title":"Transfus Apher Sci"},{"key":"1349_CR15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.transci.2004.02.004","volume":"30","author":"M Arat","year":"2004","unstructured":"Arat M, Arslan O, Ayyildiz E, Topcuoglu P, Dalva K, Ilhan O (2004) Peripheral blood stem cell apheresis for allogeneic transplants: Ibni Sina experience. Transfus Apher Sci 30:189\u2013191. doi: 10.1016\/j.transci.2004.02.004","journal-title":"Transfus Apher Sci"},{"key":"1349_CR16","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825\u2013828","journal-title":"Bone Marrow Transplant"},{"key":"1349_CR17","first-page":"250","volume":"28","author":"KM Sullivan","year":"1991","unstructured":"Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T et al (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250\u2013259","journal-title":"Semin Hematol"},{"key":"1349_CR18","first-page":"15","volume-title":"Handbook for reporting results of cancer treatment","author":"World Health Organization","year":"1979","unstructured":"World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva, pp 15\u201322"},{"issue":"24 Suppl 15","key":"1349_CR19","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2146\/ajhp070484","volume":"64","author":"J Sessions","year":"2007","unstructured":"Sessions J (2007) Chronic myeloid leukemia in 2007. Am J Health Syst Pharm 64(24 Suppl 15):S4\u2013S9. doi: 10.2146\/ajhp070484","journal-title":"Am J Health Syst Pharm"},{"key":"1349_CR20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","volume":"112","author":"H Kantarjian","year":"2008","unstructured":"Kantarjian H, O\u2019Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J (2008) Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112:837\u2013845. doi: 10.1002\/cncr.23238","journal-title":"Cancer"},{"key":"1349_CR21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/bbmt.2001.v7.pm11669214","volume":"7","author":"JH Antin","year":"2001","unstructured":"Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, Weisdorf D (2001) Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 7:473\u2013485, S1083-8791(01)50035-X","journal-title":"Biol Blood Marrow Transplant"},{"key":"1349_CR22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"1349_CR23","first-page":"163","volume":"50","author":"N Mantel","year":"1996","unstructured":"Mantel N (1996) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163\u2013170","journal-title":"Cancer Chemother Rep"},{"key":"1349_CR24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1072","unstructured":"Cox DR (1072) Regression models and life tables. J Roy Stat Soc B 34:187\u2013220","journal-title":"J Roy Stat Soc B"},{"key":"1349_CR25","first-page":"513","volume":"91","author":"A Gratwohl","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91:513\u2013521","journal-title":"Haematologica"},{"key":"1349_CR26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/bbmt.2002.v8.pm12374456","volume":"8","author":"C Junghanss","year":"2002","unstructured":"Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Storb R (2002) Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8:512\u2013520, S1083-8791(02)50012-4","journal-title":"Biol Blood Marrow Transplant"},{"key":"1349_CR27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1399-3062.2004.00075.x","volume":"6","author":"E Meijer","year":"2004","unstructured":"Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF (2004) Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis 6:171\u2013178. doi: 10.1111\/j.1399-3062.2004.00075.x","journal-title":"Transpl Infect Dis"},{"key":"1349_CR28","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1038\/sj.leu.2403105","volume":"17","author":"M Mohty","year":"2003","unstructured":"Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L, Choufi B, Bilger K, Tournilhac O, Vey N, Stoppa AM, Coso D, Gastaut JA, Viens P, Maraninchi D, Olive D, Blaise D (2003) Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 17:2168\u20132177","journal-title":"Leukemia"},{"key":"1349_CR29","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/blood.V99.6.1978","volume":"99","author":"C Junghanss","year":"2002","unstructured":"Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Little MT, Corey L, Storb R (2002) Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99:1978\u20131985. doi: 10.1182\/blood.V99.6.1978","journal-title":"Blood"},{"key":"1349_CR30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1399-3062.2003.00027.x","volume":"5","author":"A Busca","year":"2003","unstructured":"Busca A, Locatelli F, Barbui A, Ghisetti V, Cirillo D, Serra R, Audisio E, Falda M (2003) Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 5:132\u2013139. doi: 10.1034\/j.1399-3062.2003.00027.x","journal-title":"Transpl Infect Dis"},{"key":"1349_CR31","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood.V91.7.2581","volume":"91","author":"C Yu","year":"1998","unstructured":"Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, Santos E, Storb R (1998) Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91:2581\u20132587","journal-title":"Blood"},{"key":"1349_CR32","first-page":"401","volume":"91","author":"G Giraud","year":"2006","unstructured":"Giraud G, Bogdanovic G, Priftakis P, Remberger M, Svahn BM, Barkholt L, Ringden O, Winiarski J, Ljungman P, Dalianis T (2006) The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica 91:401\u2013404","journal-title":"Haematologica"},{"key":"1349_CR33","first-page":"3599","volume":"92","author":"E Carreras","year":"1998","unstructured":"Carreras E, Bertz H, Arcese W, Vernant JP, Tom\u00e1s JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Di Girolamo G, Demuynck H, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriondo A, Bosi A, Ben-Bassat I, Koza V, Gratwohl A, Apperley JF (1998) Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92:3599\u20133604","journal-title":"Blood"},{"key":"1349_CR34","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1705528","volume":"38","author":"K Ramasamy","year":"2006","unstructured":"Ramasamy K, Lim ZY, Pagliuca A, Grundy R, Devereux S, Ho AY, Mufti GJ (2006) Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 38:823\u2013824. doi: 10.1038\/sj.bmt.1705528","journal-title":"Bone Marrow Transplant"},{"key":"1349_CR35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3346\/jkms.2007.22.2.227","volume":"22","author":"I Kim","year":"2007","unstructured":"Kim I, Lee KH, Choi Y, Keam B, Koo NH, Yoon SS, Yoo KY, Park S, Kim BK (2007) Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning. J Korean Med Sci 22:227\u2013234. doi: 10.3346\/jkms.2007.22.2.227","journal-title":"J Korean Med Sci"},{"key":"1349_CR36","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","volume":"76","author":"HJ Kolb","year":"1990","unstructured":"Kolb HJ, Mitterm\u00fcller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462\u20132465","journal-title":"Blood"},{"key":"1349_CR37","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bmt.1705167","volume":"36","author":"BN Savani","year":"2005","unstructured":"Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barret AJ (2005) Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 36:1009\u20131015. doi: 10.1038\/sj.bmt.1705167","journal-title":"Bone Marrow Transplant"},{"key":"1349_CR38","first-page":"663","volume":"91","author":"M Weisser","year":"2006","unstructured":"Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ (2006) A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 91:663\u2013666","journal-title":"Haematologica"},{"issue":"suppl 1","key":"1349_CR39","first-page":"S70","volume":"39","author":"SC Bozdag","year":"2007","unstructured":"Bozdag SC, Soydan EA, Top\u00e7uoglu P, Bilgin AU, Bakanay SM, Koc H, Beksac M, Ilhan O, Ozcan M, Gurman G, Arat M (2007) Treatment of relapse after allogeneic stem cell transplantation in CML patients: imatinib only versus imatinib & DLI. Bone Marrow Transplant 39(suppl 1):S70\u2013S71. doi: 10.1038\/sj.bmt.1705631 , meeting abstract","journal-title":"Bone Marrow Transplant"},{"key":"1349_CR40","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/sj.leu.2403730","volume":"19","author":"FR Kerbauy","year":"2005","unstructured":"Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM (2005) Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 19:990\u2013997. doi: 10.1038\/sj.leu.2403730","journal-title":"Leukemia"},{"key":"1349_CR41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","volume":"101","author":"R Or","year":"2003","unstructured":"Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441\u2013445. doi: 10.1182\/blood-2002-02-0535","journal-title":"Blood"},{"key":"1349_CR42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.bmt.1705987","volume":"41","author":"O Sala-Torra","year":"2008","unstructured":"Sala-Torra O, Martin PJ, Storer B, Traina F, Sorror ML, Storb R, Sandmaier BM, Flowers ME (2008) Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. Bone Marrow Transplant 41:887\u2013893. doi: 10.1038\/sj.bmt.1705987","journal-title":"Bone Marrow Transplant"},{"key":"1349_CR43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/10428190601078464","volume":"48","author":"M Weisser","year":"2007","unstructured":"Weisser M, Schleuning M, Haferlach C, Schwerdtfeger R, Kolb HJ (2007) Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma 48:295\u2013301. doi: 10.1080\/10428190601078464","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"1349_CR44","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood-2010-01-263624","volume":"115","author":"J Pavl\u016f","year":"2010","unstructured":"Pavl\u016f J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RM (2010) Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 115(20):4018\u20134020. doi: 10.1182\/blood-2010-01-263624","journal-title":"Blood"},{"issue":"10","key":"1349_CR45","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","volume":"115","author":"S Saussele","year":"2010","unstructured":"Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, M\u00fcller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R, German CML Study Group (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115(10):1880\u20131885. doi: 10.1182\/blood-2009-08-237115","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1349-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-011-1349-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1349-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:26:44Z","timestamp":1741782404000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-011-1349-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,5]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["1349"],"URL":"https:\/\/doi.org\/10.1007\/s00277-011-1349-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2011,10,5]]}}}